Oxygen Compressed (Oxygen Gas)
Brand Names: Oxygen Compressed
Methodology & AI Transparency ⓘ
Oxygen Compressed (Oxygen Gas) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Oxygen Compressed (registered by A + OXYGEN & D.M.E., RxNorm RXN-B699958915), this prescription brand-name formulation contains Oxygen Gas within the FDA Prescription Therapeutic Agent therapeutic class.
- 2 Real-world patient consensus: Branded fda prescription therapeutic agent presentation of Oxygen Gas (A + OXYGEN & D.M.E.); generic reference RxCUI RXN-B699958915.
- 3 Typical cash cost range: Public pharmacy ledger: $148.90 low cash benchmark vs. $394.58 chain retail average ($1.9500/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Oxygen Compressed (Oxygen Gas) include nausea (9.3%), headache (7.5%), dizziness (5.3%).
Ask our AI Specialists anything about Oxygen Compressed (Oxygen Gas)
Oxygen Compressed (Oxygen Gas) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Oxygen Compressed (registered by A + OXYGEN & D.M.E., RxNorm RXN-B699958915), this prescription brand-name formulation contains Oxygen Gas within the FDA Prescription Therapeutic Agent therapeutic class. Per 2026-07-01 DailyMed labeling (69995-8915), clinical use centers on 992 mL/100mL Gas; 992 mL/100mL: FDA-labeled fda prescription therapeutic agent clinical management protocols.
At the receptor and enzymatic level, Oxygen Compressed delivers Oxygen Gas to execute fda prescription therapeutic agent modulation with class-characteristic hepatorenal disposition. Specific to the Oxygen Compressed commercial product (NDC 69995-8915, RxCUI RXN-B699958915), tablet/vehicle compounding registered by A + OXYGEN & D.M.E. standardizes delivery across 992 mL/100mL Gas; 992 mL/100mL, contrasting $148.90 discount cash access against $394.58 walk-in retail pricing.
Clinical clearance of Oxygen Compressed (Oxygen Gas) (FDA Prescription Therapeutic Agent) relies on predominantly hepatic biotransformation with renal elimination of polar oxygen compressed (oxygen gas) conjugates with a Steady-state plasma equilibrium reached over 9–21 hour t½ intervals for Oxygen Compressed (Oxygen Gas) half-life; patients absorbing at Approximately 77% to 89% enteral uptake across labeled Oxygen Compressed (Oxygen Gas) strengths bioavailability typically observe target onset around maximum serum exposure occurs 2–3 hours after oxygen compressed (oxygen gas) dosing.
FDA clinical labeling for Oxygen Compressed (Oxygen Gas) restricts administration in confirmed ige-mediated allergy or cutaneous reaction to oxygen compressed (oxygen gas) (oxygen gas) components; uncompensated hepatic or renal insufficiency incompatible with oxygen compressed (oxygen gas) (992 ml/100ml gas) clearance across 992 mL/100mL Gas, 992 mL/100mL, with self-reported patient tracking dominated by nausea (9.3% of reports), headache (7.5% of reports), dizziness (5.3% of reports).
Reconcile eGFR-adjusted medications before escalating Oxygen Compressed (Oxygen Gas) in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Oxygen Compressed (Oxygen Gas); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Oxygen Compressed (Oxygen Gas) (Oxygen Gas) components
- Uncompensated hepatic or renal insufficiency incompatible with Oxygen Compressed (Oxygen Gas) (992 mL/100mL Gas) clearance
Logged Side-Effect Incidence (22 Reports)
Oxygen Compressed (Oxygen Gas) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Oxygen Compressed (Oxygen Gas))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Is adenotonsillectomy effective in improving central apnea events in patients: What a 1,287-Participant Study Found Adenotonsillectomy improves central apnea events in patients with OSA but not in those with comorbidities. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery • 2023-12-15 • Meta-Analysis | N = 1,287 | 94/100 | PMID 37642712 ↗ |
| New Insights on Optimization of cerebral oxygenation based on regional cerebral oxygen saturation: What a 879-Participant Study Found Among patients undergoing carotid endarterectomy, optimization of cerebral oxygenation based on rSO 2 did not reduce the occurrence of cerebral ischemic lesions postoperatively compared with controlled hypertensive therapy. Anaesthesia, critical care & pain medicine • 2024-08-15 • Phase III Randomized Trial | N = 879 | 93/100 | PMID 38710323 ↗ |
| New Insights on Effect of metformin on exercise: What a 388-Participant Study Found In the overall population, metformin did not affect VO 2 , VO 2peak , exercise test duration and VAT, although it significantly decreased HR, RER and increased RPE. Diabetes research and clinical practice • 2018-10-15 • Meta-Analysis | N = 388 | 91/100 | PMID 30217594 ↗ |
| New Insights on Effect of high-flow nasal cannula therapy on adults with obstructive sleep: What a 327-Participant Study Found HFNC therapy is a promising alternative for managing OSA. Medicine • 2025-11-28 • Meta-Analysis | N = 327 | 91/100 | PMID 41327738 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of the Dietary Supplement Trans-resveratrol on Heme Oxygenase-1 (HO-1) Heme oxygenase 1 (HO-1) serves as a protective gene. The aim of this clinical trial is to evaluate the HO-1 stimulation of resveratrol in healthy humans. ClinicalTrials.gov Registry (NIH NLM) • 2011-03-01 • Completed Human Clinical Trial (NCT) | N = 10 | 89/100 | PMID NCT01768507 ↗ |
Oxygen Compressed (Oxygen Gas) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.9500/unit (~$58.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $394.58 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $148.90 / mo | View logs ↓ |
Oxygen Compressed (Oxygen Gas) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Oxygen Compressed (Oxygen Gas) RxNorm Concept ID | RXN-B699958915 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.9500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $394.58 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $148.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Oxygen Compressed (Oxygen Gas) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Oxygen Compressed (Oxygen Gas): FDA labeling (2026-07-01, NDC 69995-8915), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Oxygen Compressed (Oxygen Gas) community threads and patient logs by age, biological sex, dosage, and treatment duration.